Asset Details
Do you wish to reserve the book?
Trial of Tocilizumab in Giant-Cell Arteritis
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Trial of Tocilizumab in Giant-Cell Arteritis
Do you wish to request the book?
Trial of Tocilizumab in Giant-Cell Arteritis
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Trial of Tocilizumab in Giant-Cell Arteritis
2017
Overview
Treatment of giant-cell arteritis with tocilizumab, an interleukin-6 receptor alpha inhibitor, while prednisone was tapered over a 26-week period resulted in higher rates of sustained remission than prednisone tapering plus placebo and reduced the total prednisone dose.
Publisher
Massachusetts Medical Society
Subject
/ Antibodies, Monoclonal, Humanized - adverse effects
/ Antibodies, Monoclonal, Humanized - therapeutic use
/ Drug Administration Schedule
/ Female
/ Giant Cell Arteritis - drug therapy
/ Glucocorticoids - administration & dosage
/ Glucocorticoids - adverse effects
/ Humans
/ Ischemia
/ Male
/ Patients
/ Prednisone - administration & dosage
/ Prednisone - adverse effects
